Corneal transparency: Genesis, maintenance and dysfunction

Brain Research Bulletin

Volumn 81, Issue 2-3, 2010, Pages 198-210

  Qazi, Yureeda ^a   Wong, Gilbert ^a   Monson, Bryan ^a   Stringham, Jack ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Corneal angiogenesis; Corneal haze; Corneal lymphangiogenesis; Corneal neovascularization; Corneal transplant; Flk; Flt 1; HLA typing; PDT; PRK; VEGF

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; ALDEHYDE DEHYDROGENASE 3A1; BEVACIZUMAB; CRYSTALLIN; CYCLOOXYGENASE 2; CYCLOSPORIN A; DOXYCYCLINE; GELATINASE A; HEPARIN; KRUPPEL LIKE FACTOR 4; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PIGMENT EPITHELIUM DERIVED FACTOR; PROPOLIS; RANIBIZUMAB; RAPAMYCIN; STEROID; TACROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR PAX6; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ANTIANGIOGENIC THERAPY; ARGON LASER; CATARACT; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CORNEA DISEASE; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; CORNEA HAZE; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA STROMA; CORNEA TRANSPLANTATION; CORNEA VASCULARIZATION; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EYE DEVELOPMENT; GENE MUTATION; GLAUCOMA; GRAFT REJECTION; HERPES SIMPLEX KERATITIS; HUMAN; INFECTION; LYMPHANGIOGENESIS; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOREFRACTIVE KERATECTOMY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PTERYGIUM; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK FACTOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; HUMANS; KERATOPLASTY, PENETRATING; PHOTOREFRACTIVE KERATECTOMY;

EID: 73149125178     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.05.019     Document Type: Review

References (203)

1. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch. Ophthalmol. 110 (1992) 1392-1403
2. Abbas A., Khan B., Feroze A.H., and Hyman G.F. Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. J. Pak. Med. Assoc. 52 (2002) 476-482
3. Amano S., Rohan R., Kuroki M., Tolentino M., and Adamis A.P. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 39 (1998) 18-22
4. Ambati B.K., Anand A., Joussen A.M., Kuziel W.A., Adamis A.P., and Ambati J. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest. Ophthalmol. Vis. Sci. 44 (2003) 590-593
5. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., Albuquerque R.J., Richter E., Sakurai E., Newcomb M.T., Kleinman M.E., Caldwell R.B., Lin Q., Ogura Y., Orecchia A., Samuelson D.A., Agnew D.W., St Leger J., Green W.R., Mahasreshti P.J., Curiel D.T., Kwan D., Marsh H., Ikeda S., Leiper L.J., Collinson J.M., Bogdanovich S., Khurana T.S., Shibuya M., Baldwin M.E., Ferrara N., Gerber H.P., De Falco S., Witta J., Baffi J.Z., Raisler B.J., and Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443 (2006) 993-997
6. Ambati B.K., Patterson E., Jani P., Jenkins C., Higgins E., Singh N., Suthar T., Vira N., Smith K., and Caldwell R. Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br. J. Ophthalmol. 91 (2007) 505-508
7. Avery R.L., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., and Giust M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113 (2006) 363-372 e5
8. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J. Cataract Refract. Surg. 33 (2007) 1991-1993
9. Aydin E., Kivilcim M., Peyman G.A., Esfahani M.R., Kazi A.A., and Sanders D.R. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline. Cornea 27 (2008) 446-453
10. Azar D.T. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104 (2006) 264-302
11. Bachmann B.O., Bock F., Wiegand S.J., Maruyama K., Dana M.R., Kruse F.E., Luetjen-Drecoll E., and Cursiefen C. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch. Ophthalmol. 126 (2008) 71-77
12. Bahar I., Kaiserman I., McAllum P., Rootman D., and Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27 (2008) 142-147
13. Barry-Lane P.A., Wilson S.E., Cavanagh H.D., Petroll W.M., and Jester J.V. Characterization of SV40-transfected cell strains from rabbit keratocytes. Cornea 16 (1997) 72-78
14. Bartels M.C., Doxiadis I.I., Colen T.P., and Beekhuis W.H. Long-term outcome in high-risk corneal transplantation and the influence of HLA-A and HLA-B matching. Cornea 22 (2003) 552-556
15. Bartels M.C., Otten H.G., van Gelderen B.E., and Van der Lelij A. Influence of HLA-A, HLA-B, and HLA-DR matching on rejection of random corneal grafts using corneal tissue for retrospective DNA HLA typing. Br. J. Ophthalmol. 85 (2001) 1341-1346
16. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73 (1995) 333-346
17. Beauchamp G.R., and Knepper P.A. Role of the neural crest in anterior segment development and disease. J. Pediatr. Ophthalmol. Strabismus 21 (1984) 209-214
18. Benelli U., Lepri A., Del Tacca M., and Nardi M. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation. J. Ocul. Pharmacol. Ther. 12 (1996) 425-431
19. BenEzra D., and Foidart J.M. Collagens and non collagenous proteins in the human eye. I. Corneal stroma in vivo and keratocyte production in vitro. Curr. Eye Res. 1 (1981) 101-110
20. Bennett E.S., and Weissman B.A. Clinical Contact Lens Practice (2004), Lippincott Williams and Wilkins
21. Bock F., Konig Y., Dietrich T., Zimmermann P., Baier M., and Cursiefen C. Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104 (2007) 336-344
22. Bock F., Konig Y., Kruse F., Baier M., and Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 281-284
23. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., Zahn G., and Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci. 48 (2007) 2545-2552
24. Bock F., Onderka J., Dietrich T., Bachmann B., Pytowski B., and Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 115-119
25. Bohringer D., Spierings E., Enczmann J., Bohringer S., Sundmacher R., Goulmy E., and Reinhard T. Matching of the minor histocompatibility antigen HLA-A1/H-Y may improve prognosis in corneal transplantation. Transplantation 82 (2006) 1037-1041
26. Boote C., Dennis S., and Meek K. Spatial mapping of collagen fibril organisation in primate cornea-an X-ray diffraction investigation. J. Struct. Biol. 146 (2004) 359-367
27. Borcherding M.S., Blacik L.J., Sittig R.A., Bizzell J.W., Breen M., and Weinstein H.G. Proteoglycans and collagen fibre organization in human corneoscleral tissue. Exp. Eye Res. 21 (1975) 59-70
28. Brideau G., Makinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., Pihlajaniemi T., and Heljasvaara R. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res. 67 (2007) 11528-11535
29. In: Brightbill F.S. (Ed). Corneal Surgery: Theory, Technique & Tissue (1999), Mosby, New York
30. Brooks B.J., Ambati B.K., Marcus D.M., and Ratanasit A. Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br. J. Ophthalmol. 88 (2004) 840
31. Carrasco M.A. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 27 (2008) 743-745
32. Carrington L.M., Albon J., Anderson I., Kamma C., and Boulton M. Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors. Invest. Ophthalmol. Vis. Sci. 47 (2006) 1886-1894
33. Chakravarti S., Petroll W.M., Hassell J.R., Jester J.V., Lass J.H., Paul J., and Birk D.E. Corneal opacity in lumican-null mice: defects in collagen fibril structure and packing in the posterior stroma. Invest. Ophthalmol. Vis. Sci. 41 (2000) 3365-3373
34. Chan C.K., Pham L.N., Zhou J., Spee C., Ryan S.J., and Hinton D.R. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization. Lab. Invest. 85 (2005) 721-733
35. Chang J.H., Gabison E.E., Kato T., and Azar D.T. Corneal neovascularization. Curr. Opin. Ophthalmol. 12 (2001) 242-249
36. Chang J.H., Javier J.A., Chang G.Y., Oliveira H.B., and Azar D.T. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett. 579 (2005) 3601-3606
37. Chang L.K., Garcia-Cardena G., Farnebo F., Fannon M., Chen E.J., Butterfield C., Moses M.A., Mulligan R.C., Folkman J., and Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11658-11663
38. Chen L., Huq S., Gardner H., de Fougerolles A.R., Barabino S., and Dana M.R. Very late antigen 1 blockade markedly promotes survival of corneal allografts. Arch. Ophthalmol. 125 (2007) 783-788
39. Chew S.J., Beuerman R.W., and Kaufman H.E. Real-time confocal microscopy of keratocyte activity in wound healing after cryoablation in rabbit corneas. Scanning 16 (1994) 269-274
40. Choi Y.S., Kim J.Y., Wee W.R., and Lee J.H. Effect of the application of human amniotic membrane on rabbit corneal wound healing after excimer laser photorefractive keratectomy. Cornea 17 (1998) 389-395
41. Chu P.H., Yeh L.K., Lin H.C., Jung S.M., Ma D.H., Wang I.J., Wu H.H., Shiu T.F., and Chen J. Deletion of the FHL2 gene attenuating neovascularization after corneal injury. Invest. Ophthalmol. Vis. Sci. 49 (2008) 5314-5318
42. Chung S.A., Kim E.K., Ryu I.H., Kim J.K., and Lee H.K. Effectiveness of cultured human keratinocyte onlays on epithelial healing and clinical outcome after photorefractive keratectomy. J. Refract. Surg. 24 (2008) 826-832
43. Cintron C., Szamier R.B., Hassinger L.C., and Kublin C.L. Scanning electron microscopy of rabbit corneal scars. Invest. Ophthalmol. Vis. Sci. 23 (1982) 50-63
44. Csutak A., Silver D.M., Tozser J., Hassan Z., and Berta A. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1329-1333
45. Cursiefen C., Cao J., Chen L., Liu Y., Maruyama K., Jackson D., Kruse F.E., Wiegand S.J., Dana M.R., and Streilein J.W. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2666-2673
46. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., and Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113 (2004) 1040-1050
47. Cursiefen C., Chen L., Dana M.R., and Streilein J.W. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 22 (2003) 273-281
48. Cursiefen C., Ikeda S., Nishina P.M., Smith R.S., Ikeda A., Jackson D., Mo J.S., Chen L., Dana M.R., Pytowski B., Kruse F.E., and Streilein J.W. Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am. J. Pathol. 166 (2005) 1367-1377
49. Cursiefen C., Maruyama K., Jackson D.G., Streilein J.W., and Kruse F.E. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25 (2006) 443-447
50. Cursiefen C., Schlotzer-Schrehardt U., Kuchle M., Sorokin L., Breiteneder-Geleff S., Alitalo K., and Jackson D. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2127-2135
51. Dana M.R., Dai R., Zhu S., Yamada J., and Streilein J.W. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest. Ophthalmol. Vis. Sci. 39 (1998) 70-77
52. Dana M.R., and Streilein J.W. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 37 (1996) 2485-2494
53. Dawson D.W., Pearce S.F., Zhong R., Silverstein R.L., Frazier W.A., and Bouck N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138 (1997) 707-717
54. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., and Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
55. Dekaris I., Zhu S.N., and Dana M.R. TNF-alpha regulates corneal Langerhans cell migration. J. Immunol. 162 (1999) 4235-4239
56. DeStafeno J.J., and Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch. Ophthalmol. 125 (2007) 834-836
57. Deutsch T.A., and Hughes W.F. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am. J. Ophthalmol. 87 (1979) 536-540
58. Duke-Elder S., and Cook C. Normal and Abnormal Development, Part 1, Embryology (1963), CV Mosby, London
59. Edelhauser H.F. The balance between corneal transparency and edema: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 47 (2006) 1754-1767
60. Epstein R.J., Hendricks R.L., and Harris D.M. Photodynamic therapy for corneal neovascularization. Cornea 10 (1991) 424-432
61. Essepian J.P., Rajpal R.K., Azar D.T., New K., Antonacci R., Shields W., and Stark W.J. The use of confocal microscopy in evaluating corneal wound healing after excimer laser keratectomy. Scanning 16 (1994) 300-304
62. Estey T., Cantore M., Weston P.A., Carpenter J.F., Petrash J.M., and Vasiliou V. Mechanisms involved in the protection of UV-induced protein inactivation by the corneal crystallin ALDH3A1. J. Biol. Chem. 282 (2007) 4382-4392
63. Fernald R.D. Evolution of eyes. Curr. Opin. Neurobiol. 10 (2000) 444-450
64. Fineman M.S. Ocular paintball injuries. Curr. Opin. Ophthalmol. 12 (2001) 186-190
65. Fini M.E., Girard M.T., Matsubara M., and Bartlett J.D. Unique regulation of the matrix metalloproteinase, gelatinase B. Invest. Ophthalmol. Vis. Sci. 36 (1995) 622-633
66. Fossarello M., Peiretti E., Zucca I., and Serra A. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea 22 (2003) 485-488
67. Frueh B.E., Cadez R., and Bohnke M. In vivo confocal microscopy after photorefractive keratectomy in humans. A prospective, long-term study. Arch. Ophthalmol. 116 (1998) 1425-1431
68. Funderburgh J.L., Funderburgh M.L., Mann M.M., Corpuz L., and Roth M.R. Proteoglycan expression during transforming growth factor beta-induced keratocyte-myofibroblast transdifferentiation. J. Biol. Chem. 276 (2001) 44173-44178
69. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., Martin C., Witte C., Witte M.H., Jackson D., Suri C., Campochiaro P.A., Wiegand S.J., and Yancopoulos G.D. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3 (2002) 411-423
70. Gan L., Fagerholm P., and Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol. Scand. 82 (2004) 557-563
71. Garrett Q., Khaw P.T., Blalock T.D., Schultz G.S., Grotendorst G.R., and Daniels J.T. Involvement of CTGF in TGF-beta1-stimulation of myofibroblast differentiation and collagen matrix contraction in the presence of mechanical stress. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1109-1116
72. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 27 (2008) 1195-1199
73. Goldman J.N., and Benedek G.B. The relationship between morphology and transparency in the nonswelling corneal stroma of the shark. Invest. Ophthalmol. 6 (1967) 574-600
74. Gordon Y.J., Mann R.K., Mah T.S., and Gorin M.B. Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization. Cornea 21 (2002) 770-773
75. Griffith T.S., Brunner T., Fletcher S.M., Green D.R., and Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270 (1995) 1189-1192
76. Guerriero E., Chen J., Sado Y., Mohan R.R., Wilson S.E., Funderburgh J.L., and Sundarraj N. Loss of alpha3(IV) collagen expression associated with corneal keratocyte activation. Invest. Ophthalmol. Vis. Sci. 48 (2007) 627-635
77. Hamrah P., Liu Y., Zhang Q., and Dana M.R. The corneal stroma is endowed with a significant number of resident dendritic cells. Invest. Ophthalmol. Vis. Sci. 44 (2003) 581-589
78. Hanson I., and Van Heyningen V. Pax6: more than meets the eye. Trends Genet. 11 (1995) 268-272
79. Harooni H., Reddy V., Root T., and Ambati B. Bevacizumab for graft rejection. Ophthalmology 114 (2007) 1950
80. He J., and Bazan H.E. Epidermal growth factor synergism with TGF-beta1 via PI-3 kinase activity in corneal keratocyte differentiation. Invest. Ophthalmol. Vis. Sci. 49 (2008) 2936-2945
81. Holzer M.P., Solomon K.D., Vroman D.T., Sandoval H.P., Margaron P., Kasper T.J., and Crosson C.E. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2954-2958
82. Hos D., Bock F., Dietrich T., Onderka J., Kruse F.E., Thierauch K.H., and Cursiefen C. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest. Ophthalmol. Vis. Sci. 49 (2008) 1836-1842
83. Houck K.A., Leung D.W., Rowland A.M., Winer J., and Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267 (1992) 26031-26037
84. Huet E., Vallee B., Szul D., Verrecchia F., Mourah S., Jester J.V., Hoang-Xuan T., Menashi S., and Gabison E.E. Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: implications in tissue remodeling. FASEB J. 22 (2008) 1144-1154
85. Ihanamaki T., Pelliniemi L.J., and Vuorio E. Collagens and collagen-related matrix components in the human and mouse eye. Prog. Retin. Eye Res. 23 (2004) 403-434
86. Ikeda S., Cunningham L.A., Boggess D., Hawes N., Hobson C.D., Sundberg J.P., Naggert J.K., Smith R.S., and Nishina P.M. Aberrant actin cytoskeleton leads to accelerated proliferation of corneal epithelial cells in mice deficient for destrin (actin depolymerizing factor). Hum. Mol. Genet. 12 (2003) 1029-1037
87. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 274 (1999) 18843-18846
88. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A., and Winkler J.D. The codependence of angiogenesis and chronic inflammation. FASEB J. 11 (1997) 457-465
89. Jalbert I., and Stapleton F. The corneal stroma during contact lens wear. Cont. Lens Anterior Eye 28 (2005) 3-12
90. Jester J.V. Corneal crystallins and the development of cellular transparency. Semin. Cell Dev. Biol. 19 (2008) 82-93
91. Jester J.V., Budge A., Fisher S., and Huang J. Corneal keratocytes: phenotypic and species differences in abundant protein expression and in vitro light-scattering. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2369-2378
92. Jester J.V., Moller-Pedersen T., Huang J., Sax C.M., Kays W.T., Cavangh H.D., Petroll W.M., and Piatigorsky J. The cellular basis of corneal transparency: evidence for 'corneal crystallins'. J. Cell Sci. 112 Pt 5 (1999) 613-622
93. Jester J.V., Petroll W.M., and Cavanagh H.D. Corneal stromal wound healing in refractive surgery: the role of myofibroblasts. Prog. Retin. Eye Res. 18 (1999) 311-356
94. Johnston M.C. A radioautographic study of the migration and fate of cranial neural crest cells in the chick embryo. Anat. Rec. 156 (1966) 143-155
95. Joussen A.M., Kruse F.E., Volcker H.E., and Kirchhof B. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol. 237 (1999) 920-927
96. Kabosova A., Azar D.T., Bannikov G.A., Campbell K.P., Durbeej M., Ghohestani R.F., Jones J.C., Kenney M.C., Koch M., Ninomiya Y., Patton B.L., Paulsson M., Sado Y., Sage E.H., Sasaki T., Sorokin L.M., Steiner-Champliaud M.F., Sun T.T., Sundarraj N., Timpl R., Virtanen I., and Ljubimov A.V. Compositional differences between infant and adult human corneal basement membranes. Invest. Ophthalmol. Vis. Sci. 48 (2007) 4989-4999
97. Kaminska G.M., and Niederkorn J.Y. Spontaneous corneal neovascularization in nude mice. Local imbalance between angiogenic and anti-angiogenic factors. Invest. Ophthalmol. Vis. Sci. 34 (1993) 222-230
98. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C., and Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5 (2004) 74-80
99. Karring H., Thogersen I.B., Klintworth G.K., Enghild J.J., and Moller-Pedersen T. Proteomic analysis of the soluble fraction from human corneal fibroblasts with reference to ocular transparency. Mol. Cell Proteomics 3 (2004) 660-674
100. Kato T., Kure T., Chang J.H., Gabison E.E., Itoh T., Itohara S., and Azar D.T. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 508 (2001) 187-190
101. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64 (1997) 971-978
102. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J. Clin. Invest. 115 (2005) 2316-2319
103. Keshavarz M., Mostafaie A., Mansouri K., Shakiba Y., and Motlagh H.R. Inhibition of corneal neovascularization with propolis extract. Arch. Med. Res. 40 (2009) 59-61
104. Kim T.H., Lee D.Y., Rho J.H., Rho S.H., Yoo K.W., Ahn H.B., Yoo Y.H., and Park W.C. Application of newly developed amniotic membrane ointment for photorefractive keratectomy in rabbits. Ophthalmic Res. 38 (2006) 58-61
105. Kitazawa Y., Tokoro T., Ito S., and Ishii Y. The efficacy of cooling on excimer laser photorefractive keratectomy in the rabbit eye. Surv. Ophthalmol. 42 Suppl. 1 (1997) S82-S88
106. Kojima T., Azar D.T., and Chang J.H. Neostatin-7 regulates bFGF-induced corneal lymphangiogenesis. FEBS Lett. 582 (2008) 2515-2520
107. Kommineni V.K., Nagineni C.N., William A., Detrick B., and Hooks J.J. IFN-gamma acts as anti-angiogenic cytokine in the human cornea by regulating the expression of VEGF-A and sVEGF-R1. Biochem. Biophys. Res. Commun. 374 (2008) 479-484
108. In: Krachmer J.H., Mannis M.J., and Holland E.J. (Eds). Cornea (2005), Elsevier Mosby, New York
109. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 21 (2001) 4271-4277
110. Kubo H., Cao R., Brakenhielm E., Makinen T., Cao Y., and Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8868-8873
111. Kuchle M., Cursiefen C., Nguyen N.X., Langenbucher A., Seitz B., Wenkel H., Martus P., and Naumann G.O. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch. Clin. Exp. Ophthalmol. 240 (2002) 580-584
112. Kuo I.C. Corneal wound healing. Curr. Opin. Ophthalmol. 15 (2004) 311-315
113. Kvanta A., Sarman S., Fagerholm P., Seregard S., and Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp. Eye Res. 70 (2000) 419-428
114. Lai C.M., Brankov M., Zaknich T., Lai Y.K., Shen W.Y., Constable I.J., Kovesdi I., and Rakoczy P.E. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12 (2001) 1299-1310
115. Land M.F., and Fernald R.D. The evolution of eyes. Annu. Rev. Neurosci. 15 (1992) 1-29
116. Lee P., Wang C.C., and Adamis A.P. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 43 (1998) 245-269
117. Lepri A., Benelli U., Bernardini N., Bianchi F., Lupetti M., Danesi R., Del Tacca M., and Nardi M. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J. Ocul. Pharmacol. 10 (1994) 273-280
118. Lim M., Goldstein M.H., Tuli S., and Schultz G.S. Growth factor, cytokine and protease interactions during corneal wound healing. Ocul. Surf. 1 (2003) 53-65
119. Liu Y., Hamrah P., Zhang Q., Taylor A.W., and Dana M.R. Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J. Exp. Med. 195 (2002) 259-268
120. Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., Daly T.J., Davis S., Sato T.N., and Yancopoulos G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
121. Makinen T., Veikkola T., Mustjoki S., Karpanen T., Catimel B., Nice E.C., Wise L., Mercer A., Kowalski H., Kerjaschki D., Stacker S.A., Achen M.G., and Alitalo K. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20 (2001) 4762-4773
122. Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A., and Harris C.C. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. 6 (2000) 4739-4744
123. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., Van Rooijen N., Takenaka H., D'Amore P.A., Stein-Streilein J., Losordo D.W., and Streilein J.W. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 115 (2005) 2363-2372
124. Maurice D.M. The structure and transparency of the cornea. J. Physiol. 136 (1957) 263-286
125. McLaren J.W., Nau C.B., Kitzmann A.S., and Bourne W.M. Keratocyte density: comparison of two confocal microscopes. Eye Contact Lens 31 (2005) 28-33
126. Mihelec M., St Heaps L., Flaherty M., Billson F., Rudduck C., Tam P.P., Grigg J.R., Peters G.B., and Jamieson R.V. Chromosomal rearrangements and novel genes in disorders of eye development, cataract and glaucoma. Twin Res. Hum. Genet. 11 (2008) 412-421
127. Mimura T., Amano S., Usui T., Kaji Y., Oshika T., and Ishii Y. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp. Eye Res. 72 (2001) 71-78
128. Moller-Pedersen T. Keratocyte reflectivity and corneal haze. Exp. Eye Res. 78 (2004) 553-560
129. Moller-Pedersen T., Cavanagh H.D., Petroll W.M., and Jester J.V. Neutralizing antibody to TGFbeta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr. Eye Res. 17 (1998) 736-747
130. Moller-Pedersen T., Li H.F., Petroll W.M., Cavanagh H.D., and Jester J.V. Confocal microscopic characterization of wound repair after photorefractive keratectomy. Invest. Ophthalmol. Vis. Sci. 39 (1998) 487-501
131. Muller L.J., Pels E., Schurmans L.R., and Vrensen G.F. A new three-dimensional model of the organization of proteoglycans and collagen fibrils in the human corneal stroma. Exp. Eye Res. 78 (2004) 493-501
132. Munkhbat B., Hagihara M., Shimazaki J., Kanai N., Morita N., Gansuvd B., Kato S., Tsubota K., and Tsuji K. The impact of HLA-A matching in corneal transplantation. Tokai J. Exp. Clin. Med. 24 (1999) 63-71
133. Murata M., Shimizu S., Horiuchi S., and Taira M. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 244 (2006) 205-209
134. Murphy C., Alvarado J., and Juster R. Prenatal and postnatal growth of the human Descemet's membrane. Invest. Ophthalmol. Vis. Sci. 25 (1984) 1402-1415
135. Mwaikambo B.R., Sennlaub F., Ong H., Chemtob S., and Hardy P. Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4356-4364
136. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., Lawitts J.A., Benjamin L., Tan X., Manseau E.J., Dvorak A.M., and Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196 (2002) 1497-1506
137. Nakayasu K., Tanaka M., Konomi H., and Hayashi T. Distribution of types I, II, III, IV and V collagen in normal and keratoconus corneas. Ophthalmic Res. 18 (1986) 1-10
138. Nanjo Y., Kawasaki S., Mori K., Sotozono C., Inatomi T., and Kinoshita S. A novel mutation in the alternative splice region of the PAX6 gene in a patient with Peters' anomaly. Br. J. Ophthalmol. 88 (2004) 720-721
139. Netto M.V., Mohan R.R., Sinha S., Sharma A., Dupps W., and Wilson S.E. Stromal haze, myofibroblasts, and surface irregularity after PRK. Exp. Eye Res. 82 (2006) 788-797
140. Noden D.M. Periocular mesenchyme, neural crest and mesodermal interactions. In: Jakobiec F.A. (Ed). Ocular Anatomy, Embryology and Teratology (1982), Harper and Row, Philadelphia 97-119
141. Norman B., Davis J., and Piatigorsky J. Postnatal gene expression in the normal mouse cornea by SAGE. Invest. Ophthalmol. Vis. Sci. 45 (2004) 429-440
142. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., and Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156 (2000) 1499-1504
143. Papathanassiou M., Theodossiadis P.G., Liarakos V.S., Rouvas A., Giamarellos-Bourboulis E.J., and Vergados I.A. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am. J. Ophthalmol. 145 (2008) 424-431
144. Park W.C., and Tseng S.C. Modulation of acute inflammation and keratocyte death by suturing, blood, and amniotic membrane in PRK. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2906-2914
145. Pei Y., Reins R.Y., and McDermott A.M. Aldehyde dehydrogenase (ALDH) 3A1 expression by the human keratocyte and its repair phenotypes. Exp. Eye Res. 83 (2006) 1063-1073
146. Philipp W., Speicher L., and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2514-2522
147. Pleyer U., Milani J.K., Ruckert D., Rieck P., and Mondino B.J. Determinations of serum tumor necrosis factor alpha in corneal allografts. Ocul. Immunol. Inflamm. 5 (1997) 149-155
148. Plskova J., Duncan L., Holan V., Filipec M., Kraal G., and Forrester J.V. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 73 (2002) 210-215
149. Primbs G.B., Casey R., Wamser K., Snyder W.J., and Crean D.H. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg. Lasers 29 (1998) 832-838
150. Quantock A.J., and Young R.D. Development of the corneal stroma, and the collagen-proteoglycan associations that help define its structure and function. Dev. Dyn. 237 (2008) 2607-2621
151. Ramaesh T., Collinson J.M., Ramaesh K., Kaufman M.H., West J.D., and Dhillon B. Corneal abnormalities in Pax6+/- small eye mice mimic human aniridia-related keratopathy. Invest. Ophthalmol. Vis. Sci. 44 (2003) 1871-1878
152. Ramaesh T., Ramaesh K., Martin Collinson J., Chanas S.A., Dhillon B., and West J.D. Developmental and cellular factors underlying corneal epithelial dysgenesis in the Pax6+/- mouse model of aniridia. Exp. Eye Res. 81 (2005) 224-235
153. Ray-Keil L., and Chandler J.W. Rejection of murine heterotopic corneal transplants. Transplantation 39 (1985) 473-477
154. Ray-Keil L., and Chandler J.W. Reduction in the incidence of rejection of heterotopic murine corneal transplants by pretreatment with ultraviolet radiation. Transplantation 42 (1986) 403-406
155. Regina M., Zimmerman R., Malik G., and Gausas R. Lymphangiogenesis concurrent with haemangiogenesis in the human cornea. Clin. Exp. Ophthalmol. 35 (2007) 541-544
156. Reinhard T., Bohringer D., Enczmann J., Kogler G., Mayweg S., Wernet P., and Sundmacher R. Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching. Eye 18 (2004) 269-277
157. Reinhard T., Bonig H., Mayweg S., Bohringer D., Gobel U., and Sundmacher R. Soluble Fas ligand and transforming growth factor beta2 in the aqueous humor of patients with endothelial immune reactions after penetrating keratoplasty. Arch. Ophthalmol. 120 (2002) 1630-1635
158. Riazi-Esfahani M., Peyman G.A., Aydin E., Kazi A.A., Kivilcim M., and Sanders D.R. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 25 (2006) 801-805
159. Riordan-Eva P., and Whitcher J.P. Vaughn and Asbury's General Ophthalmology (2004), Lange Medical Books/McGraw Hill pp. 25-27
160. Ristimaki A., Narko K., Enholm B., Joukov V., and Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273 (1998) 8413-8418
161. Sakurai E., Anand A., Ambati B.K., van Rooijen N., and Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 3578-3585
162. Samolov B., Steen B., Seregard S., van der Ploeg I., Montan P., and Kvanta A. Delayed inflammation-associated corneal neovascularization in MMP-2-deficient mice. Exp. Eye Res. 80 (2005) 159-166
163. Sano Y., and Sotozono C. Role of Fas ligand in ocular tissue. Cornea 21 (2002) S30-S32
164. Schedl A., Ross A., Lee M., Engelkamp D., Rashbass P., van Heyningen V., and Hastie N.D. Influence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities. Cell 86 (1996) 71-82
165. Schmidt-Erfurth U.M., Richard G., Augustin A., Aylward W.G., Bandello F., Corcostegui B., Cunha-Vaz J., Gaudric A., Leys A., and Schlingemann R.O. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 85 (2007) 486-494
166. Schultz G., Cipolla L., Whitehouse A., Eiferman R., Woost P., and Jumblatt M. Growth factors and corneal endothelial cells: III. Stimulation of adult human corneal endothelial cell mitosis in vitro by defined mitogenic agents. Cornea 11 (1992) 20-27
167. Sellheyer K., and Spitznas M. Surface differentiation of the human corneal epithelium during prenatal development. Graefes Arch. Clin. Exp. Ophthalmol. 226 (1988) 482-488
168. Serrao S., and Lombardo M. One-year results of photorefractive keratectomy with and without surface smoothing using the technolas 217C laser. J. Refract. Surg. 20 (2004) 444-449
169. Serrao S., and Lombardo M. Corneal epithelial healing after photorefractive keratectomy: analytical study. J. Cataract Refract. Surg. 31 (2005) 930-937
170. Serrao S., Lombardo M., and Mondini F. Photorefractive keratectomy with and without smoothing: a bilateral study. J. Refract. Surg. 19 (2003) 58-64
171. Sevel D., and Isaacs R. A re-evaluation of corneal development. Trans. Am. Ophthalmol. Soc. 86 (1988) 178-207
172. Shi W., Gao H., Xie L., and Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest. Ophthalmol. Vis. Sci. 47 (2006) 3339-3344
173. Shin J.W., Min M., Larrieu-Lahargue F., Canron X., Kunstfeld R., Nguyen L., Henderson J.E., Bikfalvi A., Detmar M., and Hong Y.K. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol. Biol. Cell 17 (2006) 576-584
174. Smith R.S., Hawes N.L., Kuhlmann S.D., Heckenlively J.R., Chang B., Roderick T.H., and Sundberg J.P. Corn1: a mouse model for corneal surface disease and neovascularization. Invest. Ophthalmol. Vis. Sci. 37 (1996) 397-404
175. Stojanovic A., Ringvold A., and Nitter T. Ascorbate prophylaxis for corneal haze after photorefractive keratectomy. J. Refract. Surg. 19 (2003) 338-343
176. Stramer B.M., and Fini M.E. Uncoupling keratocyte loss of corneal crystallin from markers of fibrotic repair. Invest. Ophthalmol. Vis. Sci. 45 (2004) 4010-4015
177. Stuart P.M., Pan F., Plambeck S., and Ferguson T.A. FasL-Fas interactions regulate neovascularization in the cornea. Invest. Ophthalmol. Vis. Sci. 44 (2003) 93-98
178. Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., Sato T.N., and Yancopoulos G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
179. Swamynathan S.K., Katz J.P., Kaestner K.H., Ashery-Padan R., Crawford M.A., and Piatigorsky J. Conditional deletion of the mouse Klf4 gene results in corneal epithelial fragility, stromal edema, and loss of conjunctival goblet cells. Mol. Cell Biol. 27 (2007) 182-194
180. Sundarraj N., and Willson J. Monoclonal antibody to human basement membrane collagen type IV. Immunology 47 (1982) 133-140
181. Tisdale A.S., Spurr-Michaud S.J., Rodrigues M., Hackett J., Krachmer J., and Gipson I.K. Development of the anchoring structures of the epithelium in rabbit and human fetal corneas. Invest. Ophthalmol. Vis. Sci. 29 (1988) 727-736
182. Totan Y., Aydin E., Cekic O., Cihan Dagloglu M., Borazan M., Daglioglu K., and Gultek A. Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr. Eye Res. 23 (2001) 291-297
183. Usui T., Yamagami S., Kishimoto S., Seiich Y., Nakayama T., and Amano S. Role of macrophage migration inhibitory factor in corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 48 (2007) 3545-3550
184. Veikkola T., Karkkainen M., Claesson-Welsh L., and Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60 (2000) 203-212
185. Vetrugno M., Maino A., Cardia G., Quaranta G.M., and Cardia L. A randomised, double masked, clinical trial of high dose vitamin A and vitamin E supplementation after photorefractive keratectomy. Br. J. Ophthalmol. 85 (2001) 537-539
186. Wang F. UVA/riboflavin-induced apoptosis in mouse cornea. Ophthalmologica 222 (2008) 369-372
187. Wang I., Kao C.W., Liu C., Saika S., Nishina P.M., Sundberg J.P., Smith R.S., and Kao W.W. Characterization of Corn1 mice: Alteration of epithelial and stromal cell gene expression. Mol. Vis. 7 (2001) 20-26
188. Watari K., Nakao S., Fotovati A., Basaki Y., Hosoi F., Bereczky B., Higuchi R., Miyamoto T., Kuwano M., and Ono M. Role of macrophages in inflammatory lymphangiogenesis: enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation. Biochem. Biophys. Res. Commun. 377 (2008) 826-831
189. White R.R., Shan S., Rusconi C.P., Shetty G., Dewhirst M.W., Kontos C.D., and Sullenger B.A. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5028-5033
190. Wigle J.T., Harvey N., Detmar M., Lagutina I., Grosveld G., Gunn M.D., Jackson D.G., and Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21 (2002) 1505-1513
191. Wilson S.E. Role of apoptosis in wound healing in the cornea. Cornea 19 (2000) S7-12
192. Wu P.C., Kuo H.K., Tai M.H., and Shin S.J. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28 (2009) 103-104
193. Wulle K.G. Electron microscopy of the fetal development of the corneal endothelium and Descemet's membrane of the human eye. Invest. Ophthalmol. 11 (1972) 897-904
194. Yamada J., Dana M.R., Zhu S.N., Alard P., and Streilein J.W. Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation. Arch. Ophthalmol. 116 (1998) 1351-1357
195. Yamagami S., Dana M.R., and Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 21 (2002) 405-409
196. Yanoff M., and Duker J.S. Ophthalmology (2004), Mosby, St. Louis, MO
197. Yoeruek E., Spitzer M.S., Tatar O., Aisenbrey S., Bartz-Schmidt K.U., and Szurman P. Safety profile of bevacizumab on cultured human corneal cells. Cornea 26 (2007) 977-982
198. Yoeruek E., Ziemssen F., Henke-Fahle S., Tatar O., Tura A., Grisanti S., Bartz-Schmidt K.U., and Szurman P. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 86 (2008) 322-328
199. Yoon K.C., You I.C., Kang I.S., Im S.K., Ahn J.K., Park Y.G., and Ahn K.Y. Photodynamic therapy with verteporfin for corneal neovascularization. Am. J. Ophthalmol. 144 (2007) 390-395
200. You I.C., Kang I.S., Lee S.H., and Yoon K.C. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. (2008)
201. Yu H., Wu J., Li H., Wang Z., Chen X., Tian Y., Yi M., Ji X., Ma J., and Huang Q. Inhibition of corneal neovascularization by recombinant adenovirus-mediated sFlk-1 expression. Biochem. Biophys. Res. Commun. 361 (2007) 946-952
202. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., and Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (2002) 4797-4806
203. Zieske J.D., Guimaraes S.R., and Hutcheon A.E. Kinetics of keratocyte proliferation in response to epithelial debridement. Exp. Eye Res. 72 (2001) 33-39